Log in

NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

$18.98
+0.26 (+1.39 %)
(As of 12/16/2019 07:33 AM ET)
Today's Range
$18.48
Now: $18.98
$19.07
50-Day Range
$14.84
MA: $17.87
$19.63
52-Week Range
$13.24
Now: $18.98
$19.73
Volume1.21 million shs
Average Volume1.53 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$151.86 million
Book Value$1.72 per share

Profitability

Net Income$-80,330,000.00

Miscellaneous

Employees281
Market Cap$2.78 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.


Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.05. The biopharmaceutical company earned $46.20 million during the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The firm's quarterly revenue was up 80.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Halozyme Therapeutics.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$195-205 million, compared to the consensus revenue estimate of $$204.86 million.

What price target have analysts set for HALO?

3 Wall Street analysts have issued 1-year target prices for Halozyme Therapeutics' shares. Their forecasts range from $16.00 to $27.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

What is the consensus analysts' recommendation for Halozyme Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.

What are Wall Street analysts saying about Halozyme Therapeutics stock?

Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
  • 1. According to Zacks Investment Research, "Halozyme has promising collaboration deals related to its ENHANZE technology with several small and large pharma companies. These deals generate the majority of revenues for the company. Blockbuster drugs like Herceptin and Rituxan use ENHANZE for subcutaneous administration, which boosts Halozyme’s royalties. Development of subcutaneous formulation of another blockbuster drug, Darzalex is encouraging. Restructuring initiatives following failure of PEGPH20 is also encouraging. Halozyme’s shares have outperformed the industry so far this year. However, the company’s dependence on collaboration partners for revenues remains a concern. Rising competition for partnered drugs is also a concern. Estimates have been stable ahead of Q3 earnings. The company has a positive record of earnings surprise in the recent quarters." (11/7/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019)

Has Halozyme Therapeutics been receiving favorable news coverage?

Media headlines about HALO stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Halozyme Therapeutics.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 12,420,000 shares, an increase of 64.9% from the November 14th total of 7,530,000 shares. Based on an average trading volume of 1,556,800 shares, the short-interest ratio is presently 8.0 days. Approximately 9.0% of the shares of the company are short sold. View Halozyme Therapeutics' Current Options Chain.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Transocean (RIG).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
  • Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
  • Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
  • Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
  • Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.08%), Pictet Asset Management Ltd. (2.06%), Eagle Asset Management Inc. (1.05%), Fisher Asset Management LLC (0.80%), Carillon Tower Advisers Inc. (0.72%) and Man Group plc (0.50%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.

Which institutional investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Neo Ivy Capital Management, Russell Investments Group Ltd., Mackay Shields LLC, Squarepoint Ops LLC, Janney Montgomery Scott LLC and Alps Advisors Inc.. View Insider Buying and Selling for Halozyme Therapeutics.

Which institutional investors are buying Halozyme Therapeutics stock?

HALO stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Millennium Management LLC, Man Group plc, California Public Employees Retirement System, State Street Corp, First Trust Advisors LP and Zebra Capital Management LLC. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $18.98.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.78 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel